JAK inhibition: the key to treating myeloproliferative neoplasm?

MPN blast phase: clinical challenge and assessing response.

JAK2 inhibitors in the treatment of myeloproliferative neoplasms.

Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.

Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.

Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase.

Guideline for the diagnosis and management of myelofibrosis.

Evolution of clinical trial endpoints in chronic myeloid leukemia: efficacious therapies require sensitive monitoring techniques.

Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors.

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS).